Analyst Ratings For Cronos Group Inc (NASDAQ:CRON)
Today, Cowen initiated coverage on Cronos Group Inc (NASDAQ:CRON) with a Market Perform.
There are 3 Hold Ratings, 2 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Cronos Group Inc (NASDAQ:CRON) is Hold with a consensus target price of $15.46 per share, a potential 27.96% downside.
Some recent analyst ratings include
- 3/5/2019-Cronos Group Inc (NASDAQ:CRON) has coverage initiated with a Market Perform rating
- 2/25/2019-Cronos Group Inc (NASDAQ:CRON) has coverage initiated with a Underperform ➝ Underperform rating and $21.92 price target
- 2/5/2019-Cronos Group Inc (NASDAQ:CRON) gets downgraded to Hold by GMP Securities
- 1/18/2019-Cronos Group Inc (NASDAQ:CRON) has coverage initiated with a Sector Outperform ➝ Sector Outperform rating
- 11/15/2018-Cronos Group Inc (NASDAQ:CRON) had its Hold ➝ Average rating reiterated by Canaccord Genuity with a $9.00 price target
- 5/4/2018-Cronos Group Inc (NASDAQ:CRON) had its Buy rating reiterated by Beacon Securities
About Cronos Group Inc (NASDAQ:CRON)
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Recent Trading Activity for Cronos Group Inc (NASDAQ:CRON)
Shares of Cronos Group Inc closed the previous trading session at 21,46 −0,25 1,15 % with 22 shares trading hands.
